Aims-To determine whether mutant p53 alleles harboured by malignant tumours of the oral cavity were also present in previous premalignant lesions at the same site. Methods-Paraffin embedded tumour specimens along with their premalignant counterparts were analysed for p53 alterations using inumunohistochemistry, microge of dissection, polymerase chain reaction amplification, and DNA sequencing. 
Results-Malignant lesions from five of eight patients showed overexpression of -Head p53 protein by immunohistochemistry. ry Upon DNA sequencing, two of these five specimens had p53 mutations. Of the five patients whose cancers showed p53 overexpression by immunohistochemistry, three had previous premalignant lesions that also had immunohistochemically de To determine whether or not the increased cellular level of p53 protein was due in each case to mutation in p53, we performed direct genomic sequencing of PCR amplified product of exons 5, 6, 7, and 8, which include the majority of known mutated sites. None of the premalignant lesions showed p53 mutations within this region (table) . Two of the eight cancer patients (patient 3 and patient 7) had two missense mutations in p53 (table) . One patient (P3) had two missense mutations, one at the second base of codon 273 (CGT to CAT) causing an amino acid change from arginine to histidine, and the other at codon 164 (AAG to AAT) causing a lysine to asparagine change (figure). The other (P7) had mutation at codon 143 (GTG to TTG) causing an amino acid change from valine to leucine ( figure) .
In all three cases, the sequencing gels displayed a wild type band in the same position as the mutant band (figure), indicative of two alleles. That there was no loss of heterozygosity was confirmed by microsatellite analysis (data not shown). The other three malignant tumours and the three premalignant lesions which stained positive with antibody to p53 did not reveal mutations within the regions sequenced. ,tailed in Methods. Panels reports, the premalignant specimen was obdfrom an antisense tained from tissue in proximity to the tumour, primer. All three gels and may have arisen from the same progenitor ntensity to the mutant cell that gave rise to the tumour proper. In the s are heterozygous for codons. present report, the premalignant and malignant samples were obtained from the same site but at different times. Even though in two cases both premalignant and counterpart malignant lesions stained with antibody to p53, only the this study was that malignant specimen had a mutation in p53 tse cancer tissue had within the region assayed. ilso manifested p53
These results show that p53 protein acnt lesion at the same cumulation, but not gene mutation, may occur tumour developed. at a very early stage oforal cavity tumorigenesis, that immunohisto-suggesting that the accumulation ofp53 protein can occur very early was mutated by a p53 mutation independent in head and neck tumorigenesis. The number of patients presented here is necessarily small because of the scarcity of cohorts in which metachronous lesions are available for study. This report is the first to describe p53 staining in head and neck cancer and in a corresponding earlier premalignant sample from the same patient.
It is possible that mutations may have occurred outside the region sequenced (that is, exons 5-8). However, other studies in which the complete cDNA mutations were screened found very few mutations outside this region. 30 Alternatively, staining could be facilitated by activating expression of other genes encoding proteins that might interact with or stabilise p53, such as that which encodes the murine mechanism.
